Retatrutide Side Effects: What Studies Report

Retatrutide is an investigational triple agonist of the GIP, GLP-1 and glucagon receptors that has been studied in randomised, placebo-controlled trials in people with obesity and in people with type 2 diabetes. This page summarises what peer-reviewed publications state about its adverse-event profile. This page is for educational purposes only and is not medical advice; consult a licensed physician about any prescription medicine, adverse effect or treatment decision.

Evidence tier: Established — the findings below come from peer-reviewed randomised controlled trials, a registrational trial-design publication, and systematic reviews and meta-analyses indexed in PubMed. Retatrutide is a prescription-pathway investigational compound developed by Eli Lilly and Company; any brand or product name associated with it is a trademark of its owner, and PeptideU is not affiliated with or endorsed by any manufacturer, pharmacy or seller.

What the Published Trials Studied

In a phase 2 trial in adults with obesity, researchers randomly assigned participants to retatrutide 1 mg, 4 mg (initial dose 2 mg), 4 mg, 8 mg (initial dose 2 mg), 8 mg (initial dose 4 mg), 12 mg (initial dose 2 mg) or placebo once weekly for 48 weeks, and reported mean body-weight reductions ranging from 8.7% at 1 mg to 24.2% at 12 mg at week 48 compared with 2.1% for placebo (PMID 37366315). A separate phase 2 trial in adults with type 2 diabetes compared retatrutide doses with placebo and with dulaglutide 1.5 mg over 36 weeks and reported greater reductions in glycated haemoglobin and body weight in the retatrutide groups (PMID 37385280). A systematic review and meta-analysis of randomised controlled trials pooled these data and reported both the efficacy signal and a higher frequency of gastrointestinal adverse events with retatrutide than with placebo (PMID 40291085).

The registrational programme now under way, described in a trial-design publication, covers obesity, obstructive sleep apnoea and knee osteoarthritis in people with obesity, and its authors set out the safety and efficacy endpoints planned for those studies (PMID 41090431).

Gastrointestinal Events: What Studies Report

Gastrointestinal effects dominate the published adverse-event tables. In the obesity phase 2 trial, the most common adverse events in the retatrutide groups were mild-to-moderate gastrointestinal events that occurred primarily during dose escalation and were reported less often when a lower starting dose and slower escalation were used (PMID 37366315). The type 2 diabetes trial likewise reported mild-to-moderate gastrointestinal events as the most frequent adverse events, again clustered in the escalation period (PMID 37385280).

The pooled analysis of retatrutide randomised trials reported that nausea, vomiting, diarrhoea and constipation were more frequent with retatrutide than with placebo, with frequency generally tracking dose (PMID 40291085). A narrative review of retatrutide summarised the same pattern, describing gastrointestinal intolerance as the principal tolerability limitation identified in phase 2 work (PMID 40563436).

Why escalation schedules appear in the reports

Because the trials tested several different starting doses that converged on the same maintenance dose, the study design itself allowed researchers to compare tolerability across escalation speeds; the obesity trial reported that groups reaching the same maintenance dose from a lower starting dose had fewer gastrointestinal events (PMID 37366315). Reviews of emerging obesity pharmacotherapy describe stepwise escalation as a recurring feature of incretin-based trial protocols for this reason (PMID 39952695).

Heart Rate and Cardiometabolic Measures: What Studies Report

The obesity phase 2 trial reported dose-dependent increases in heart rate that peaked at week 24 and declined thereafter (PMID 37366315). Reviews of triple-agonism therapies note that glucagon-receptor activity distinguishes retatrutide from dual and single incretin agonists and discuss heart rate and energy-expenditure effects as part of that pharmacology (PMID 40741227). Broader reviews of the obesity pipeline place these observations alongside reported improvements in glycaemic and lipid measures seen in phase 2 work (PMID 38302593).

Body Composition Findings: What Studies Report

A substudy of the phase 2 trial in people with type 2 diabetes used imaging to characterise body-composition change and reported the relative contributions of fat mass and lean mass to total weight reduction (PMID 40609566). Reviews of weight-management pharmacotherapy discuss lean-mass change as an outcome that is increasingly measured in incretin trials rather than inferred from total weight alone (PMID 40865172).

Discontinuation and Serious Events: What Studies Report

The pooled meta-analysis of retatrutide randomised trials reported adverse-event-related discontinuation and serious adverse events alongside efficacy outcomes, and concluded that the tolerability pattern was consistent with the incretin drug class (PMID 40291085). A systematic review of GLP-1 receptor agonists for weight loss in adults without diabetes reported that gastrointestinal adverse events were the most common reason for treatment discontinuation across trials of this class (PMID 39761578). A safety-focused review of GLP-1 medicines for type 2 diabetes and obesity summarised class-level considerations, including gastrointestinal effects and monitoring issues clinicians weigh when these agents are prescribed (PMID 38843460).

Because retatrutide has not completed its registrational programme, long-term adverse-event data are limited to the durations studied; the design publication for the ongoing trials states which safety outcomes will be collected over longer follow-up (PMID 41090431).

Questions the Published Literature Does Not Answer

Several questions asked about retatrutide fall outside what the peer-reviewed trials and reviews above examined. Reporting that gap accurately matters more than filling it with speculation.

Preparation, dilution and post-mixing shelf life

The trials cited here administered study drug supplied and handled under clinical-trial pharmacy conditions; their publications do not describe out-of-clinic preparation, diluent selection, mixing procedures, post-mixing shelf life or storage temperatures (PMID 37366315, PMID 37385280). For a prescription-pathway medicine, product-specific stability and handling information sits in the manufacturer's approved labelling and in pharmacy references, not in trial abstracts, and PeptideU does not publish preparation, mixing or handling procedures for any drug. Questions about the physical state or integrity of a dispensed product are handled by the dispensing pharmacist or prescriber rather than by inference from clinical-trial literature.

Milligram-to-syringe-unit conversions

The published trials expressed doses in milligrams per week, not in syringe graduation marks, and none of the verified publications describes a volumetric conversion (PMID 37366315). Any conversion between a milligram amount and marks on a syringe depends on the concentration of a specific dispensed product, which is a prescribing and dispensing matter rather than a published research finding, so no conversion is provided here.

Testosterone, androgens and hormone therapy

None of the verified publications in this set reported testosterone concentrations, androgen outcomes, or the co-administration of testosterone therapy with retatrutide. The closest published hormone-adjacent evidence is the body-composition substudy, which reported fat-mass and lean-mass changes in people with type 2 diabetes rather than sex-hormone measures (PMID 40609566). Statements that retatrutide raises or lowers testosterone are therefore not supported by the trials summarised on this page, and interactions with any prescribed hormone therapy are a question for the prescribing clinician.

Combinations with CJC-1295, ipamorelin or other growth-hormone secretagogues

CJC-1295 and ipamorelin are growth-hormone-axis peptides that were not evaluated in any of the retatrutide trials cited here; the obesity and type 2 diabetes phase 2 trials compared retatrutide with placebo, and the diabetes trial additionally with dulaglutide 1.5 mg, with no growth-hormone secretagogue arm (PMID 37366315, PMID 37385280). Reviews of the obesity pipeline and of triple-agonist therapies likewise discuss incretin-based combinations and amylin or other metabolic targets rather than growth-hormone secretagogue stacking (PMID 39952695, PMID 40741227). In short, no randomised human data on such combinations appear in the verified literature, so no safety or interaction profile can be described, and this page offers no combination guidance.

How Retatrutide Sits Within Its Drug Class

Reviews comparing agents describe retatrutide as extending incretin pharmacology by adding glucagon-receptor agonism to GIP and GLP-1 activity, and they group its reported adverse-event pattern with that of other incretin-based medicines (PMID 40563436). Class reviews of GLP-1 medicines report that gastrointestinal effects are the dominant tolerability issue and that most events are mild to moderate and escalation-related (PMID 38843460, PMID 39761578). Clinical overviews of weight-management treatment place pharmacotherapy within a broader framework that also includes behavioural and surgical options, and they note that comparative long-term safety data for newer agents remain in development (PMID 40865172, PMID 38302593).

Readers comparing published reports should note that adverse-event frequencies come from specific trial populations, doses and durations; the study designs differ, and the reported percentages are not interchangeable between an obesity trial and a diabetes trial (PMID 37366315, PMID 37385280). Again, this page is educational and is not medical advice; decisions about any prescription medicine belong with a licensed physician.

References

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (The New England Journal of Medicine, 2023)
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (Lancet, 2023)
• Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials (Proceedings (Baylor University Medical Center), 2025)
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism, 2026)
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial (The Lancet Diabetes & Endocrinology, 2025)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (Diabetes Care, 2024)
• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials (Annals of Internal Medicine, 2025)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• What is the pipeline for future medications for obesity? (International Journal of Obesity, 2025)
• Triple Agonism Based Therapies for Obesity (Current Cardiovascular Risk Reports, 2025)
• Weight management treatment in obesity (Medicina Clinica, 2025)